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Abstract
Background: The zinc metalloprotease ADAMTS13 is a multidomain protein that cleaves von Willebrand Factor (VWF) and is
implicated in Thrombotic Thrombocytopenic Purpura (TTP) pathogenesis. Understanding the mechanism of this protein is
an important goal. Conformation sensitive antibodies have been used to monitor protein conformation and to decipher the
molecular mechanism of proteins as well as to distinguish functional and non-functional mutants.
Methodology/Principal Findings: We have characterized several antibodies against ADAMTS13, both monoclonal and
polyclonal. We have used flow cytometry to estimate the binding of these antibodies to ADAMTS13 and demonstrate that
antibodies raised against the TSP and disintegrin domains detect conformation changes in the ADAMTS13. Thus for
example, increased binding of these antibodies was detected in the presence of the substrate (VWF), mainly at 37uC and not
at 4uC. These antibodies could also detect differences between wild-type ADAMTS13 and the catalytically deficient mutant
(P475S). The flow cytometry approach also allows us to estimate the reactivity of the antibody as well as its apparent affinity.
Conclusions/Significance: Our results suggest that these antibodies may serve as useful reagents to distinguish functional
and non-functional ADAMTS13 and analyze conformational transitions to understand the catalytic mechanism.
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Introduction
ADAMTS13 is a protease that cleaves the von Willebrand
Factor (VWF) within intact blood vessels under shear stress [1–3].
VWF is a large glycoprotein secreted by vascular endothelial cells
as multimers. At a region of vascular injury, the multimeric form
of VWF initiates the clotting process by adhering to platelets. A
reduction or elimination of the protease activity of ADAMTS13
results in the VWF multimers remaining uncleaved in the
circulating blood stream, which ultimately leads to intravascular
thrombosis and an associated disorder known as Thrombotic
Thrombocytopenic Purpura (TTP) [4,5]. Thus ADAMTS13 plays
a critical role in maintaining intravascular homeostasis.
ADAMTS13 is a member of the ADAMTS (a disintegrin and
metalloproteinase with thrombospondin motifs) family of proteins
[6] and is secreted by almost all tissues but primarily by hepatic
stellate cells [7–10]. The ADAMTS family of proteins are secreted
metalloproteases characterized by multiple domains [11]. The
domain structure of ADAMTS13 contains a signal peptide,
propeptide, a metalloprotease, disintegrin, a thrombospondin type
1 domain (TSP1), a cystein rich domain, a spacer domain, seven
TSP1 repeats and two C-terminal CUB (C1r/C1s, Urinary
EGFand Bone morphogenetic protein) domains. Although all
ADAMTS proteins have characteristic multi domains, the
ADAMTS13 is unique in having two additional C-Terminal
CUB domains and an unusually short propeptide. Moreover,
unlike other ADAMTS members, ADAMTS13 is catalytically
active prior to secretion from the cells [12]. The metalloprotease
domain is the catalytic domain and responsible for the protease
activity [13]. The region from the disintegrin to the spacer
domains is involved in substrate recognition [14] while the distal
C-terminal TSP1 repeats and CUB domains are also necessary for
its activity under flowing conditions [15,16]. The role of the
cysteine-rich domain is more controversial [14,17]. It is thus
evident that the ADAMTS13-VWF interaction is complex; several
domains of the protein are involved in the regulation of VWF
cleavage.
Antibodies sensitive to the conformation of a protein have been
successfully used to understand the structural organization of
proteins, distinguish their functional and non-functional forms,
elucidate molecular mechanisms, and establish the role of different
domains of multidomain proteins. For example, conformation-
sensitive antibodies against native and denatured bovine somato-
tropin have been used successfully to study its folding, stability,
thermal denaturation and refolding [18]. The specific monoclonal
antibody 5D3 was used to differentiate functional and non-
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substrate-binding sites but differed in the formation of a catalytic
intermediate [19]. A monoclonal antibody against the CRIB
domain of the N-WASP protein that specifically recognized the
activated protein was used to localize it within cells [20].
Conformation-sensitive UIC2 could identify different classes of
drug modulators of P-glycoprotein and the molecular mechanism
underlying their interactions based on mutations in the multidrug
resistance gene (MDR1; ABCB1) which led to different conforma-
tions of the molecule [21,22]. Similarly, a conformation-sensitive
antibody was successfully used to identify the disease-causing
mutation in Copper/Zinc Superoxide Dismutase [23].
ADAMTS13 is a multi-domain protein with complex interac-
tions with its substrate. Antibodies sensitive to different confor-
mations could thus be potentially useful to understand the
regulation and mechanism of ADAMTS13-mediated catalysis.
In this report, we studied and defined new conformation-sensitive
antibodies to ADAMTS13. We examined the monoclonal
antibodies Wh2-11-1 and Wh2-22-1A, which are specific to the
TSP1-4 and Disintegrin domains, respectively, and the polyclonal
antibody BL154G that is specific to the metalloprotease domain of
ADAMTS13, for their sensitivity to conformation. Here we show
their ability to detect conformation changes in the ADAMTS13
protein under various conditions in which the protein normally
undergoes changes in conformation such as changes due to
temperature, and in the presence of its substrate. We use flow
cytometry to measure the affinities and reactivity of these
antibodies. We demonstrate that both the reactivity and the
apparent affinity (concentration required for half-maximal bind-
ing) of these antibodies is altered by the addition of substrate
(VWF). This change is observed mainly at 37uC but not at 4uC
and occurs in the wild-type protein but not in a catalytically
inactive mutant. These results indicate that the ADAMTS13
antibodies are conformation-sensitive.
Results
Using antibodies against ADAMTS13 in flow cytometric
assays
Monitoring the antigen-antibody interaction of a protein in an
intact cell using flow cytometry has the significant advantage that
the antibody can explore the tertiary structure of a functional
protein in its native environment. In addition, it is plausible that
some antibodies bind to epitopes which are sensitive to the
conformation of the protein which may have functional or
diagnostic importance. Soejima and coworkers have characterized
antibodies that recognize several distinct domains of ADAMTS13;
nonetheless the antibodies were raised by inoculating mice with the
intact protein and not peptide fragments (Soejima, personal
communication). In Fig. 1A we demonstrate that the antibodies
Wh2-22-1A (that recognizes the disintegrin-like domain) and Wh-2-
11-1 (that recognizes the thrombospondin type 1–4 domains) bind
to intracellular ADAMTS13. Human embryonic kidney (HEK293)
cellsweretransientlytransfected withADAMTS13plasmidDNAas
described in the Materials and methods and expression of
ADAMTS13 in this system has previously been shown to be
equivalent to that in human stellate liver cells, which are known to
express ADAMTS13 at high levels [25]. The cells were permea-
bilized and incubated with the anti ADAMTS13 antibodies and
washed to remove excess antibody that did not react with the
antigen. The cells were then incubated with a secondary antibody
tagged with Alexa Flour 488 (see Materials and methods for details).
The control cells were incubated with the isotype IgG2a antibody
followed by incubation with the secondary antibody. The
fluorescence associated with the Alexa Flour 488 was measured in
a flow cytometer and Fig. 1A shows the distribution of fluorescence
intensity in a population of 10,000 cells following the different
treatments. Cells treated with the IgG2a control antibody show low
levels of fluorescence that establishes the baseline for nonspecific
interactions and interactions with the secondary antibody alone.
However, when the cells were treated with Wh2-11-1 or Wh2-22-
1A antibodies prior to addition of the secondary antibody there is a
dramatic increase in the fluorescence from a median fluorescence
value of 23.5 to 165.48 or 67.32. It is thus clear that these antibodies
Figure 1. Flow cytometry based assay to detect intracellular
ADAMTS13. (A) HEK293 cells transiently transfected with ADAMTS13
plasmid DNA were permeabilized and incubated with the anti
ADAMTS13 antibodies Wh2-22-1A or Wh2-11-1 and an isotypic control
antibody Anti-mouse IgG2a. The cells were washed to remove excess
antibody and treated with an Alexa Flour 488 labeled secondary
antibody. The fluorescence associated with the Alexa Flour 488 was
measured in a flow cytometer and histograms showing the distribution
of fluorescence intensity in a population of 10,000 cells following the
different treatments are depicted. Cells treated with the control antibody
show low levels of fluorescence that establishes the baseline for
nonspecific interactions with the control and secondary antibodies.
Histograms show permeabilizedHEK293 cellsincubated with the isotypic
control antibody (red line), Wh2-22-1A (blue line) or Wh2-11-1 (green
line) prior to incubation with the secondary antibody. (B) Apparent
affinity and reactivity of the anti-ADAMTS13 mAbs Wh2-22-1A (N) and
Wh2-11-1 (&) was estimated using the flow cytometry based assay
depicted in (A) above. The cells were incubated with increasing amounts
of the antibodies and the median fluorescence (of histograms similar to
those depicted in (A) above) were plotted as a function of mg antibody.
doi:10.1371/journal.pone.0006506.g001
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in an immunoblot assay also bind to intracellular recombinant
ADAMTS13 and flow cytometry can be used to characterize this
interaction (Geetha S et al unpublished results).
Dose-dependent binding of ADAMTS13-specific
monoclonal antibodies
In the previous section we have demonstrated that a flow
cytometric assay can be used to quantitatively assess the binding of
antibodies against ADAMTS13 to the intracellular protein. These
experiments demonstrate that by permeabilizing cells it is possible
for anti-ADAMTS13 antibodies to access the interior of cells as
well as bind to the intracellular ADAMTS13. Thus this technique
can potentially be used to study the dose-dependent saturating
binding of the ADAMTS13-specific monoclonal antibodies. We
therefore used the flow cytometry-based assay to estimate the
concentration required for half-maximal binding of the monoclo-
nal antibodies Wh2-11-1 and Wh2-22-1A to ADAMTS13 which
is a measure of the apparent affinity of the antibody for the protein
(Fig. 1B). Our results show that although both antibodies bind
specifically to ADAMTS13 (Fig. 1A) the concentration of
antibodies required for half-maximal binding as well as the Vmax
are very different. This is not surprising as these antibodies
recognize different epitopes on ADAMTS13. Moreover, the
importance of estimating the reactivity of antibodies that may be
sensitive to the conformation of the protein is that such antibodies
would bind with increased or decreased efficiency when the
conformation of the epitope is altered.
The mAb Wh2-11-1 shows increased reactivity to
ADAMTS13 in the presence of substrate (VWF)
Enzymes undergo conformational changes during the catalytic
process and conformation sensitive antibodies offer a means of
monitoring these changes. The substrate for ADAMTS13 is a large,
multimeric glycoprotein VWF (the monomeric unit is 260 kDa, and
the multimer is greater than 10,000 kDa) and it would be useful to
establish whether the binding of VWF affects the kinetic parameters
(apparent Kd or Vmax) associated with the binding of the
monoclonal antibodies to intracellular ADAMTS13. Such a
measurement assumes that there is no interaction between the
anti-ADAMTS13 antibody and VWF. As this is an important
control we tested antibodies raised against ADAMTS13 as well as
against VWF in an ELISA assay using VWF bound to collagen
coated wells. Our results show that none of the anti-ADAMTS13
antibodies tested interacts with the VWF; on the other hand three
different anti-VWF antibodies (which provide a positive control)
show a strong signal (Fig. 2A). Secondly the fact that VWF is a large
multimeric protein raisesthe concern that VWFmay not enter cells,
eventhosethat havebeen permeabilized.Weused a flow cytometric
assay similar to that described in Fig. 1A to monitor VWF which is
added to permeabilized cells and incubated for 10 minutes at 37uC.
Fig. 2B shows that HEK293 cells transiently transfected with VWF
show a higher fluorescence signal (associated with the binding of the
anti-VWF monoclonal antibody AXL205) than the untransfected
cells. However addition of extrinsic VWF to the untransfected
control cells results in the intracellular accumulation of VWF
(Fig. 2C) as evidenced by the fact that the fluorescence signal
following incubation with the anti-VWF antibody is at a level
comparable to that observed in cells transfected with VWF.
However, when the same experiment was performed with
unpermeabilized cells, the histograms with the secondary antibody
alone and the anti-VWF monoclonal antibody AXL205 could not
be distinguished (Data not given), suggesting that we are detecting
VWF that has entered the cell and not merely adsorbed on the cell
surface. Taken together, these results clearly show: (i) Permeablizia-
tion of cells permit the entry of large molecules such as antibodies
and VWF. (ii) Anti-ADAMTS13 and anti-VWF antibodies can be
used (in conjugation with the appropriate fluorescence tagged
secondary antibody) to detect intracellular levels of the two proteins.
(iii) Flow cyotmetry offers a means of quantifying intracellular levels
of ADAMTS13and VWF.Ourexperimental system can, therefore,
be used to study the effect of VWF binding to ADAMTS13 as
estimated by changes in the dose-dependent binding of conforma-
tion sensitive antibodies to ADAMTS13.
We analyzed the effect of the ADAMTS13 substrate, VWF, on
the reactivity of the mAb Wh2-11-1. Incubation of VWF with
ADAMTS13 at 37uC, resulted in a .10-fold increase in the
reactivity of Wh2-11-1 (P,0.001). Moreover, this increase in
reactivity is accompanied by a ,5.5-fold decrease in the apparent
affinity of the mAb for ADAMTS13 (concentration required for
half-maximal binding increases from 9.7 mg/ml to 50.6 mg/ml;
Fig. 3A). These results indicate that binding of VWF alters the
conformation of the ADAMTS13 epitope resulting in a decreased
apparent affinity of the mAb Wh2-11-1. The presence of the
substrate may be expected to protect some binding sites on
ADAMTS13 and if this were the case, one may expect a decrease in
the reactivity of the mAb. However, Fig. 3B shows that the
increasedreactivityofthemAbWh2-11-1inthepresenceofVWFis
concentration dependent and saturable. The fact that there is a
large increase in the reactivity of the antibody strongly indicates that
the mAb is sensitive to conformational changes in ADAMTS13.
Furthermore, we have shown (Fig. 2A) that all three tested
ADAMTS13 antibodies do not bind to VWF and therefore the
increaseinbinding inthepresence ofVWF resultsonlyfromspecific
binding to ADAMTS13. We also demonstrate (Fig. 3C) that while
the mAb Wh-2-11-1 shows an increase in reactivity on the binding
of substrate (VWF) in cells transfected with rADAMTS13, an
antibody to the V5 tag on rADAMTS13 (which is not sensitive to
the conformation of the epitope) shows negligible change.
We have suggested, above, that the changes in ADAMTS13
within cells detected by the conformation sensitive antibodies may
be related to catalytic activity. This proposition is based, in part,
on the observation that an increased (and concentration
dependent) binding of antibodies occurs in the presence of the
substrate, WVF. The presentation of the large VWF to the
intracellular ADAMTS13 however requires that the cells be
permeabilized. It is therefore important to demonstrate that
permeabilization per se does not affect the activity of ADAMTS13.
ADAMTS13-mediated cleavage of the synthetic 73-amino-acid
peptide, FRETS-VWF73 can be detected using fluorescence
resonance energy transfer and this assay has increasingly been
used to quantify ADAMTS13 activity [24]. We used this assay to
measure the initial rates of intracellular ADAMTS13 proteolytic
activity in control cells and those that had been permeabilized as
described in the Materials and methods. Our results show that the
activity of intracellular ADAMTS13 is indistinguishable in
untreatted cells and those that were permeabilized (Fig. 4).
Taken together, these data suggest that the interaction of VWF
and ADAMTS13 results in increased accessibility of the Wh2-11-1
epitope. The Wh2-11-1 epitope is TSP1-4 (thrombospondin type-1-
4 motif) and TSP1 repeats of ADAMTS family members have been
shown to be important for substrate recognition and cleavage [16].
The reactivity of mAb Wh2-11-1 is sensitive to
temperature
Conformational changes in proteins (particularly those that
accompany enzyme catalysis) are often energy dependent; thus,
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PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6506Figure 2. Identification of intracellular VWF. (A) ELISA assay showing reactivity of different antibodies to VWF. VWF was allowed to bind
collagen coated wells and antibodies raised against ADAMTS13 (BL154G, Wh2-22-1A and Wh2-11-1) [35], VWF (MO616, A0082 and AXL205) or the
anti-V5 (V5) as well as secondary antibodies (all HRP conjugated - anti-goat, anti-mouse or anti-rabbit) were added to the wells to measure their
reactivity. The positive control was an antibody against VWF provided by the manufacturer of the kit. The antibodies were used at a dilution of
1:1000, in plates coated with VWF. (B) Control HEK293 cells and those transiently transfected with VWF were analyzed by flow cytometry for
intracellular VWF. Cells were treated with either secondary antibody alone or the anti-WVF monoclonal antibody AXL205 followed by the secondary
antibody. The left panel depicts cells that were unpermeabilized while the right panel shows cells that were permeabilized prior to treatment with
the antibodies. The histograms show cells treated with the secondary antibody alone (red line) or the anti-VWF antibody followed by the secondary
antibody (green line). (C) The ADAMTS13-transduced HEK293 was harvested 24 hours post-transduction and 500 ml of VWF was added to these cells
followed by incubation at 37uC for 10 min. The cells were then immunostained with AXL205 and the appropriate secondary antibody and analyzed
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at 4uCa n d3 7 uC in the presence of the substrate VWF (Fig. 5).
Incubation of ADAMTS13 with VWF at 37uC prior to addition of
the mAb resulted in increased reactivity (Bar I, Fig. 5). However,
whenthemAbwasaddedpriortoVWFtherewasreducedreactivity
with the mAb (Bar II, Fig. 5), suggesting that binding of the mAb
hinders the conformational changes that accompany ADAMTS13-
mediated proteolysis. This is consistent with the finding that
autoantibodies that recognize various domains of ADAMTS13
(including those similar to the Wh2-11-1 epitope) result in acquired
TTP [26] and the fact that the immunogenicity of clotting factors
such as factor VIII is a significant impediment to the treatment of
hemophilia [27]. This observation also provides additional evidence
that Wh2-11-1 interacts with the functional intracellular
ADAMTS13 [12]. Finally, addition of VWF at 4uC, either before
or after addition of the mAb, does not affect the reactivity of the
mAb (Bars III and IV, Figure 3). It would be expected that like most
proteolytic enzymes, the optimal activity of ADAMTS13 cleavage
occurs between 30uCa n d3 7 uC [28] and there is minimal activity at
4uC. Thus, it would be unlikely that VWF-induced conformational
changes would occur at 4uC. The results depicted in Fig. 5 suggest
that the changes in the reactivity of the mAb Wh2-11-1 reflect
conformational changes that accompany catalysis.
Binding of the anti-ADAMTS13 antibody BL154G
prevents substrate-induced conformational changes
The data presented above shows that the monoclonal antibody
Wh2-11-1 can be used to report conformational changes in
ADAMTS13 such as those resulting from interactions with the
substrate. Several reports have indicated that autoantibodies against
ADAMTS13 inhibit this protease [5,29–33]. We therefore studied
the effect of the polyclonal antibody BL154G on conformation
changes in ADAMTS13 as well as its function. In Fig. 6A we show
that addition of VWF increases the reactivity of the polyclonal Ab
BL154G in a concentration dependent manner, similar to our
observation with Wh2-11-1. In this experiment permeabilized cells
transfected with an ADAMTS13 encoding vector were incubated
with increasing concentrations of VWF for 10 min at 37uC. Cells
were then exposed to the polyclonal antibody BL154G for 30 min,
cells were washed and incubated with the secondary antibody
Figure 3. VWF increases the immunoreactivity of anti-
ADAMTS13 antibody Wh2-11-1. (A) Serial dilutions of the mAb
Wh2-11-1 were allowed to bind to ADAMTS13 from human embryonic
cells (HEK293 cells) in the absence (&) or presence (N) of 100-500 ml
from VWF stock. (B) Either 1 mg( &)o r5mg(N) of the mAb Wh2-11-1
were allowed to bind ADAMTS13 in the presence of increasing
concentrations of VWF. The binding of the antibody in both
experiments was monitored using flow cytometry and the data plotted
using the curve-fitting software Graphpad Prism. (C) The binding of the
mAb Wh2-11-1 was compared to that of the anti-V5 antibody in the
absence or presence of VWF using flow cytometry. The histograms
represent: Wh2-11-1 alone (red), Wh2-11-1 in the presence of VWF
(green), anti-V5 alone (pink) and anti-V5 in the presence of VWF (blue).
The figures represent data from one of three independent experiments.
doi:10.1371/journal.pone.0006506.g003
Figure 4. Permeabilization of cells does not affect the activity
of intracellular ADAMTS13. Activity of ADAMTS13 in control cells
(N) and those treated with the permeabilization reagent (IntraPrep
TM
Beckman Coulter) (&) was measured using the FRETS-VWF73 assay (for
details of permeabilization and the FRETS-VWF73 assay see Materials
and methods). Following treatment the cells were lyzed and the
cytoplasmic fraction was concentrated and equal volumes were used
from control and permeabilized cells in the FRET-based assay. The
amount of total protein was subsequently estimated and equal
amounts of protein were loaded for an immunoblot using the anti-V5
antibody. Relative amounts of ADAMTS13 were estimated from the
immunoblot and the data presented here are corrected based on these
values. The figure represents data from three independent experiments.
doi:10.1371/journal.pone.0006506.g004
Characterizing ADAMTS13
PLoS ONE | www.plosone.org 5 August 2009 | Volume 4 | Issue 8 | e6506tagged with (FITC rabbit anti-goat). The ADAMTS13 transduced
cells show a higher fluorescence signal than the control (untrans-
fected) cells and the fluorescence signal is enhanced in a
concentration-dependent manner with the addition of increasing
amounts of VWF. However, when ADAMTS13 was treated with
the antibody prior to the addition of VWF, there was no change in
reactivity (Fig. 6B). Thus, binding of the polyclonal antibody
appears to inhibit conformational changes in the protease. It is
plausible that these conformational changes are associated with
catalysis and could reflect the functional state of the ADAMTS13
protein.Weused the FRET-based assaydescribed abovetomonitor
the activity of ADAMTS13 activity before and after treatment with
the antibody, BL154G. The data depicted in Fig. 6C clearly shows
that pre-treatment of ADAMTS13 with BL154G significantly
inhibits catalytic activity.
Intracellular and secreted forms of ADAMTS13 show
comparable proteolytic activity
We have shown above that monoclonal antibodies sensitive to
protein conformation may be useful in the repertoire of tools used
to study ADAMTS13. One drawback of the flow cytometry based
assay described here is that it can only be performed in intact cells.
We have therefore studied the conformation changes in intracel-
lular ADAMTS13. It is thus important to demonstrate that
intracellular ADAMTS13 shows comparable activity to the
secreted form which is the physiologically relevant form of the
protein. An earlier study has demonstrated that the intracellular,
pro-ADAMTS13, cleaves the VWF factor intracellularly [12].
This observation was based on a qualitative assay where
proteolytic cleavage of VWF was determined on an immunoblot
and has not been independently verified. We have used the FRET
based assay described in Fig. 6C to compare the activities of the
intracellular and secreted forms of ADAMTS13 (Fig. 7). The
results depicted are corrected for the relative amounts of
intracellular and secreted forms of ADAMTS13 detected on an
immunoblot when equal amounts of total protein were loaded on
the gel. Our results clearly show that consistent with the previous
study [12] both secreted and intracellular ADAMTS13 exhibit
proteolytic activity. However using the FRET based assay which
permits better quantification, it is possible to estimate that the
initial rates are slightly higher in the secreted ADAMTS13 (Fig. 7).
A catalysis-deficient mutant of ADAMTS13 does not
show VWF-induced changes in conformation
Fujimura and coworkers have studied the effects of common
mutations and polymorphisms in ADAMTS13 on protease activity
Figure 5. VWF induces conformational changes in ADAMTS13
at 37uC which are inhibited by prior labeling with the mAb
Wh2-11-1. ADAMTS13 from HEK293 cells was incubated with the mAb
Wh2-11-1 and VWF under the following conditions: (I) ADAMTS13 was
treated with VWF at 37uC prior to addition of Wh2-11-1. (II) ADAMTS13
was treated with Wh2-11-1 at 37uC followed by the addition of VWF. (III)
ADAMTS13 was treated with VWF at 4uC prior to addition of Wh2-11-1.
(IV) ADAMTS13 was treated with Wh2-11-1 at 4uC followed by the
addition of VWF. *Reactivity of ADAMTS13 to Wh2-11-1 is significantly
higher (p,.001) in the presence of VWF at 37uC. **There is no
significant difference between the reactivity of Wh2-11-1 to ADAMTS13
in the presence or absence of VWF at 4uC (p=0.083). Binding of mAb
was monitored by flow cytometry. The figure represents data from one
of five independent experiments.
doi:10.1371/journal.pone.0006506.g005
Figure 6. The pAb BL154G inhibits VWF-induced conforma-
tional changes in ADAMTS13. (A) ADAMTS13 was incubated with
increasing concentrations of VWF for 30 min at 37uC followed by the
addition of the pAb BL154G. (B) ADAMTS13 was incubated with BL154G
antibody for 30 min at 37uC. Increasing concentrations of VWF were
then added to the samples. Both sets of samples were analyzed by flow
cytometry. Histograms represent binding of mAb in the presence of 0
(red), 100 (purple), 250 (green) and 500 (blue) ml of VWF stock. The
figures represent data from one of three independent experiments. (C)
Activity of ADAMTS13 in the absence (N) and presence (&) of the pAb,
BL154G, measured using the FRETS-VWF73 assay.
doi:10.1371/journal.pone.0006506.g006
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similar expression to the wild type protein but reduced activity.
They estimated the activity based on the accumulation of
monomers and rate of reduction in multimeric level as identified
by sodium dodecyl sulphate-agarose gel electrophoresis. Using the
more quantitative FRET based assay for ADAMTS13 activity
described in the previous section we confirmed these results
(Fig. 8A). Our results show a clear decrease in the rate of FRET-
VWF73 cleavage in mutant enzyme compared to the wild type.
Even more significant is our observation that the change in
conformation of ADAMTS13 on binding of VWF reported by the
antibody BL154G does not occur in the mutant protein. We show
that incubation of wild-type ADAMTS13 with VWF followed by
addition of the antibody BL154G results in an increase in the
median fluorescence in a flow cytometry assay (Fig. 8B, bars II &
II). However when the experiment is conducted using the mutant
ADAMTS13, we did not observe any change in the median
fluorescence on addition of VWF. Similar results were obtained
with the mAb Wh-2-11-1, where the fluorescence intensity
increased 3.5 fold for the wild-type ADANTS13, but only 1.9
fold for the mutant (data not given). Considering that the wild-type
and mutant express at equivalent levels (see above) and that the
wild-type and mutant proteases show different reactivity to the
antibodies suggests different conformations for these forms. Also,
while addition of VWF to wild-type ADAMTS13 results in
increased reactivity of both the mAb and the pAb, a similar
increase in the reactivity of the mAb and the polyclonal Ab is not
observed in the mutant ADAMTS13. These results provide
further evidence that only the functional ADAMTS13 undergoes
conformational changes on interacting with the VWF.
Discussion
Soejima and coworkers have recently generated several
monoclonal antibodies that recognize distinct functional regions
of the ADAMTS13 molecule [35]. We found that several of these
are sensitive to changes in the conformation of ADAMTS13. Here
we characterize in detail three antibodies (the monoclonal
antibodies Wh2-11-1 and Wh2-22-1A as well as the polyclonal
antibody BL154G). We have used flow cytometry to study the
interactions between the antibody and ADAMTS13 so that the
native conformation of the ADAMTS13 protein could be
preserved. The apparent affinities of all three antibodies were
altered in the presence of the substrate (VWF). These antibodies
also showed different reactivity to ADAMTS13 in the presence of
VWF, but only at 37uC and not at 4uC. Furthermore if the
Figure 7. The activity is secreted and intracellular ADAMTS13.
Activity of secreted (N) and intracellular ADAMTS13 (&). Activity of
intracellular ADAMTS13 was measured using the FRETS-VWF73 assay
described in Fig. 4. The secreted ADAMTS13 was collected from the
media which was concentrated using a Centriprep 30 centrifrugal filter
device. The data were corrected for amount of ADAMTS13 in each
sample as described in Fig. 4. The activities for the secreted and
intracellular ADAMTS13 were 17.3 arbitrary units/min/unit protein and
8.8 arbitrary units/min/unit protein respectively. Typical traces from
three independent experiments are depicted.
doi:10.1371/journal.pone.0006506.g007
Figure 8. A functionally deficient mutant of ADAMTS13 shows
minimal conformation change in the presence of VWF. (A)
Activity of wild-type (&) and the P475S mutant (N) ADAMTS13s were
measured by the FRET-VWF73 assay as described previously. Inset
shows the activity of wild-type (filled bar) and the mutant (empty bar)
ADAMTS13. (B) Wild-type and the P475S mutant ADAMTS13 were
incubated with either BL154G alone (filled bars) or in the presence of
500 ml of VWF stock (empty bars). The VWF was incubated with
ADAMTS13 prior to addition of the polyclonal Ab. Binding of polyclonal
Ab was monitored by flow cytometry. The figures represent data from
one of three independent experiments.
doi:10.1371/journal.pone.0006506.g008
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VWF there was no change in the reactivity. Addition of VWF to
intracellular ADAMTS13 required the permeabilization of cells,
however the procedure had no effect on ADAMTS13 activity.
These results suggested that these antibodies (and particularly
Wh2-11-1) may be useful as conformation-sensitive antibodies to
understand the mechanism of ADAMTS13.
Earlier work has shown that Wh2-11-1 recognizes an epitope
that corresponds to the TSP1-4 motifs [35] which do not directly
interact with the substrate (VWF), but was shown under shear
stress to take part in the recognition of the substrate. Consistent
with this view is our observation that VWF does not inhibit
binding of Wh2-11-1 to ADAMTS13. In this study we show
concentration-dependent reactivity of Wh2-11-1 to ADAMTS13
and demonstrate that the addition of VWF results in a dramatic
increase in reactivity and a smaller decrease in the apparent
affinity of the antibody for ADAMTS13. As there is an
approximately 8-fold increase in the immunoreactivity, it is
unlikely that the change in reactivity is a consequence of
competition between VWF and Wh2-11-1. We also show in this
study that the VWF-induced increase in the reactivity of the
antibody occurs at 37uC but not at 4uC (Fig. 3). Also significant is
the fact that pre-treatment of ADAMTS13 with Wh2-11-1 prior to
addition of VWF does not result in an increase in the
immunoreactivity. Taken together, these results suggest that
although the TSP1-4 domains may not interact directly with the
VWF, the consequence of VWF binding is a conformation change
(possibly transient) that results in a greater exposure of the Wh2-
11-1 epitope, which might mimic shear stress conditions. In
addition, the fact that Wh2-11-1 binds to its epitope with different
affinities in the presence and absence of VWF suggests that the
conformation of this epitope is altered, which might occur in these
circumstances. This hypothesis is moreover supported by the fact
that the conformational change is energetically driven (i.e. does
not occur at 4uC). These results suggest that Wh2-11-1
preferentially binds to a transient conformation during the
enzymatic hydrolysis of VWF.
Conformational transitions almost always accompany enzymat-
ic activity, protein-protein interactions or transport mediated by
membrane proteins [36]. The ability to track these transitions
experimentally has often proved useful in understanding molecular
mechanisms. These conformational changes are often identified by
fluorescence, EPR or other probes crosslinked to the proteins
being studied [37,38]. This crosslinking approach has two
significant disadvantages. Perturbations related to the chemical
modifications of the protein often affect the function and/or
kinetics of the enzyme or transporter [39]. Secondly, it is
extremely difficult to localize probes in the functional domain of
the protein. Here again, a common experimental technique
involves the replacement of native cysteines in the protein of
interest and introduction of cysteines at desired positions followed
by chemical cross-linking using thiol-reactive probes [37-40]. Such
an approach involves the use of mutants as well as chemical cross-
linking. A relatively non-invasive means of following functional
transitions, on the other hand, is the use of conformation-sensitive
antibodies. There are several examples in the literature of the
usefulness of this approach [18–21,41]. Extensive characterization
of the ADAMTS13 antibody Wh2-11-1 demonstrates that the
immunoreactivity of this antibody is sensitive to the conformation
of ADAMTS13. Our results also show that the reactivity of this
antibody is sensitive to the binding of VWF (which is the substrate
of ADAMTS13 for proteolytic degradation). Thus we demonstrate
that the interaction of VWF with ADAMTS13 brings about
changes in conformation at the TSP1-4 domains (where no direct
interactions have been shown to occur). This view is supported by
emerging concepts about the role of the ADAMTS13 domains
[16,42]. We also show that a conformation-sensitive antibody can
distinguish between the wild-type ADAMTS13 and the mutant
P475S. This mutant has been shown previously to have reduced
enzymatic activity [34] and we have confirmed in this study that
the mutant has decreased hydrolytic activity for FRET-VWF73 (a
fluorogenic substrate of ADAMTS13). Finally, the large (,8-fold)
increase in the reactivity of Wh2-11-1 in the presence of VWF is
not observed in the mutant ADAMTS13. This observation
suggests that the conformational change reported by Wh2-11-1
is not an artifact but represents a reaction intermediate during the
ADAMTS13-mediated proteolysis of VWF. A significant under-
lying assumption of these proposals is that the intracellular and
secreted ADAMTS13 (which is physiologically relevant) both
exhibit proteolytic activities. A previous study concluded that this
was indeed so [12], we confirm this observation in our system in
the current study using a more quantitative assay than was used
previously. We suggest that the reactivity of the antibodies Wh2-
11-1, BL154G and Wh2-22-1A (particularly Wh2-11-1) can be
used as a sensitive assay to distinguish functional and non-
functional ADAMTS13 as well as to analyze conformational
transitions associated with function. For example a recent study
determined that several Swedish families with a synonymous
mutation (i.e. one with no change in the amino acid sequence) in
the Factor IX gene nonetheless exhibit hemophilia B [43]. The
authors were however unable to provide a mechanistic explana-
tion for this important observation. We have demonstrated
previously that even silent mutations can affect protein folding
and function by altering the rate of protein synthesis [44].
Antibodies sensitive to protein conformation are an invaluable tool
in testing such hypotheses.
Materials and Methods
Cell culture and cell lines
The ADAMTS13-expressing kidney and liver cell lines
HEK293 (human embryonic kidney cells; American Type Culture
Collection Manassas, VA), and LX2 (human stellate liver cells; a
gift from Dr. Friedman, Mt. Sinai, NY) were maintained in
DMEM media (Dulbecco’s Modified Eagle Medium) with 10%
fetal bovine serum (FBS), 50 mg/mL penicillin, 50 mg/mL
streptomycin and 5 mM L-glutamine (all obtained from Invitro-
gen
TM, Carlsbad, CA). Cells were incubated at 37uC, in 5% CO2
with humidity.
Site-directed mutagenesis
Site-directed mutagenesis was performed on the wild-type
vector – ADAMTS13 cDNA containing a carboxy-terminal V5
tag subcloned into a pcDNA4 plasmid (a gift from Dr. J. Evan
Sadler, Washington University, St. Louis) – using the Stratagene
QuikChangeH II XL Site-Directed Mutagenesis Kit (La Jolla, CA).
Transient transfection
HEK293 cells were transiently transfected with ADAMTS13
plasmid DNA in order to highly express the ADAMTS13 protein.
Lipofectamine 2000 by Invitrogen was used to transfect the cells,
following the manufacture protocol. Six hours post-transduction,
the medium was replaced with Opti-MEM (Invitrogen) medium
and cells were maintained in this medium for 24 h.
VWF collagen ELISA assay
Von Willebrand Factor (VWF) stock solution was prepared by
dissolving 1000 IU (CSL Behring, Marburg, Germany) in 20 ml
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Five hundred ml of VWF from the stock solution was added to
collagen coated wells (LifeDiagnostics von Willebrand Factor Antigen
Assay, Frenchs Forest, Australia). After three washes the primary
antibodies were added for 1 hour incubation (BL154G (Bethyl
laboratories, Montgomery, TX, USA), Wh2-22-1A and Wh2-11-1
against ADAMTS13; M0616, A0082 and AXL205 (Dako
Corporation, Carpintaria, CA, USA) against VWF and anti-V5
(Invitrogen) against the V5 tag) followed by additional washes and
secondary antibody incubation, again for 1 hour. The plate was
read at 450 nm. Results were analyzed using Soft Max Pro and
Thermo Max microplate reader (Molecular Devices, Sunnyvale,
CA, USA).
Detection of ADAMTS13 protein by flow cytometry
Following trypsinization, cells were washed with PBS, and
fixative reagent (IntraPrep
TM Beckman Coulter, Marseille, France)
(100 ml per each 5610
5 cells) was added to the pellet. The cells were
vortexed and incubated at room temperature for 15 minutes. After
the incubation period, the cells were washed again with PBS for 5
minutes at 1400 RPM in 27uC and the supernatant was aspirated.
Permeabilization reagent (IntraPrep
TM Beckman Coulter) (100 ml
per 5610
5 cells) was added to the cell pellet and incubated at room
temperature for 5 minutes. Following permeabilization, PBS was
added to the solution in order to distribute the cells for the various
staining procedures and treatments. Cells were incubated with
VWF (0, 10, 100, 250, and 500 ml from VWF stock) after the
primary antibody was added (at varioustemperatures – as described
in the Results section for each experiment). Other cells were
incubated with the substrate (the same concentrations) before
incubation with the primary antibody, and the rest of the cells were
incubated with VWF without a primary antibody and only received
a secondary antibody, thus serving as controls for non-specific
binding in the absence or presence of VWF. In addition, we
employed isotopic antibody control (Anti-mouse IgG2a, Invitrogen)
to ensure the specificity of the ADAMTS13 antibodies. The
concentrations of the primary and secondary antibodies were kept
constant through all the treatments. Several dilutions from stock of
1 mg/ml of the monoclonal Wh2-11-1, monoclonal Wh2-22-1A
and polyclonal BL154G (Bethyl) antibodies or 1:100 dilution from
1 mg/ml anti-V5 antibody(Invitrogen) wereadded to cells and cells
were incubated at 37uC for 30 minutes. In some cases, cells were
pre-incubated with VWF substrate for 10 minutes at 37uC. Alexa-
488 Goat anti-Mouse IgG secondary antibody (Invitrogen) at 37uC
for 30 minutes was used for anti-V5, Wh2-11-1 and Wh2-22-1A
antibodies while Rabbit anti-Goat IgG (Bethyl) was used for the
primary ADAMTS13 antibody BL154G. Certain amounts of VWF
were added again to each tube following the addition of the
respective specific secondary antibodies. Between adding the
primaryantibody and the secondary and after adding the secondary
antibody, cells were washed with PBS (Invitrogen) 0.1% bovine
serum albumin (BSA; Sigma) for 5 minutes and the supernatant was
aspirated. The cells were then analyzed using the Becton Dickinson
FACSCalibur. Median values were calculated using the ‘‘stat’’
programofCellQuestbyBectonDickinsonandwerethenplottedin
Excel.We haverecently reported thedevelopmentandvalidation of
the assay to detect intracellular ADAMTS13 by flow cytometry as
well as the detailed protocols [45].
Preparation of cell lysate and concentrated medium
All experiments were performed on endogenous and recombi-
nant ADAMTS13-expressing cells. We used HEK293 cells,
ADAMTS13-HEK293 transduced cells and LX2 stellate liver
cells. Twenty-four hours after the transfection, media was collected
and concentrated 24–fold using 30 kDa cut-off Centriprep
concentrating vials (Millipore, Billerica, MA, USA). The concen-
trated media was then kept at -20uC. The cells were washed with
5 ml of chilled PBS (Invitrogen) lysed with lysis buffer (1 M Tris-
HCl, 5 M NaCl, 100% Triton X-100, Protease Inhibitor Cocktail,
PMSF) and then stored at -20uC. A Bradford protein assay (Bio-
Rad, New York, NY) was used to determine the total protein
concentration for these lysates and concentrated media samples
according to the manufacture’s protocol.
Immunoblotting
The samples were boiled with SDSPAGE running buffer for 5
minutes, sonicated for 10 minutes and electrophoresed on 3–8%
NUPAGE Tris-Acetate SDS-PAGE gels (Invitrogen). The proteins
were then transferred to a nitrocellulose membrane at constant
current. The ADAMTS13 protein was detected using the Wh2-
11-1 monoclonal primary antibody and anti-mouse HRP
secondary antibody (Invitrogen).
FRET-VWF73 assay
FRET-VWF73 (Peptides International, Louisville, KY, USA) is
a flourogenic substrate developed to test the activity of
ADAMTS13 [24]. The activity of the protein was tested using a
GeminiMax plate reader. Readings were taken every 5 minutes for
one hour at a 340 nm excitation and 450 nm emission. The
FRET-VWF73 peptide was prepared as a stock concentration of
100 mM according to the manufacturer’s instructions and was
stored at 220uC. The stock was diluted 25 fold in reaction buffer
containing 5 mM Tris-HCl, 25 mM CaCl2, and 0.005% Tween-
20 (Sigma) at pH 6. The test sample was prepared in a 1:3 dilution
with reaction buffer and 3% NaCitrate solution (Sigma). The
FRET-VWF73 and sample dilutions were combined just prior to
the kinetic assay. Analysis of the results revealed the rate of
ADAMTS13 activity as change in fluorescence per unit protein
per minute.
Statistical analysis
A two-tailed unpaired T-test was used to compare the sample
means of immunostaining results at the same concentration levels
of antibody. It tests the null hypothesis that two normally
distributed independent random samples have equal means. In
the homoscedastic case, the test statistic is computed as:
t~




   r , s2~
P n1
i~1





   2
n1{1 ðÞ z n2{1 ðÞ
,
Where  x x1, x x2 are the sample means, n1,n2 are the sample sizes,
and s2 is the unbiased estimate of the variance. The p-values 0.001
are statistically significant at a=0.05 level.
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